network. Phenotypic assessments suggest that RBPMS-high hES-VSMCs are less motile and less proliferative compared to RBPMS-low cells correlating with the phenotypic properties of mature VSMCs (figure 2).

Our findings indicate that RBPMS drives contractile splicing programs, possibly influencing phenotype by acting as a master regulatory hub for genes critical for VSMC identity and function.

Conflict of Interest None

REFERENCES

Introduction
Endothelial dysfunction is central to the development of atherosclerosis. Previous approaches studying endothelial gene expression in relation to atherogenesis have utilised in vitro cell culture or in vivo models sampling endothelium from the carotid arteries or aortic arch. Endothelial gene expression studies in coronary atherosclerotic plaques in vivo

Abstract BS18 Figure 1

Abstract BS18 Table 1  Biological pathways to which differentially expressed genes belong to
PULMONARY ARTERY SMOOTH MUSCLE CELLS THROUGH A NOVEL SELECTIVE PDE1C:PROSTACYCLIN RECEPTOR INTERACTION
1Zaher Al Bakour, 1James Hislop, 2James Guy Breitenbacher, 1Fiona Murray. 1University of Aberdeen, Aberdeen, UK; 2Conveps Therapeutics

Introduction Pulmonary arterial hypertension (PAH) is associated with increased phosphodiesterase 1C (PDE1C) expression and activity, which accounts in part, to lower cAMP accumulation and increased proliferation of pulmonary artery smooth muscle cells (PASMC) isolated from PAH-patients: PDE1C expression correlates with increased PASMC proliferation. PASMC also have increased prostacyclin (IP) receptor expression that limits their response to IP agonists. Recently, a phosphodiesterase 1 inhibitor (16K) has been developed for central nervous system disorders and tested in preclinical studies. Using PASMC we aimed to investigate the response of 16K, alone and together with the prostacyclin (IP) receptor agonist seleipag, to provide evidence for the therapeutic utility of PDE1 inhibitors for PAH.

Methods Human PASMCs were cultured under normoxia and hypoxia (1% O2, 72 hr) to investigate PDE1C expression (Real-time PCR) and the effect of 16K (0.01-10μM) and Selexipag (0.001-1μM) on PASMCs proliferation (MTS) and cAMP accumulation (ELISA). PDE1C, PDE1A and PDE4B cDNA (SinoBiological) and IP cDNA (cDNA.org) were used to be stably overexpressed in HEK293 (Lipofectamine 2000, ThermoFisher). Lysosomal inhibitor (chloroquine, 100 μM) and pro teaseol and pro teaseolization (MG132, 10 μM) were used to assess IP receptor degradation, via fluorescence microscopy. Q5 sit-directed mutagenesis kit was used for prostacyclin receptor PDZ domain manipulation. Experiments were performed at least three times and data presented as means ± S.E.M and compared by ANOVA or student t-test.

Results PDE1C mRNA is increased in PASMC exposed to hypoxia (62.9 ± 6.9-fold increase vs. normoxia, p<0.05, n=3), which correlated with increased PDE1C protein expression and activity: increased PDE1C expression correlated with lower cAMP (103.4 ± 4.9 vs. 56.3 ± 3.5 pmol/million cells in normoxic and hypoxic PASMC, respectively) and increased proliferation. PDE1 inhibition (16K) restored cAMP levels (56.3 ± 3.5 vs. 106.2 ± 8.8 pmol/million cells in control and 16K-treated hypoxic PASMC, respectively) and increased PASMC relaxation and inhibited hypoxia-induced proliferation (21 ± 0.03 % decrease, MTS assay). Selexipag-mediated cAMP accumulation and relaxation, which was blunted in hypoxic-PASMC, was restored by 16K pre-treatment. In PASMC and HEK293 we found overexpression of PDE1C correlated with increased pro teaseolization of the IP receptor, which blunted receptor mediated responses. Overexpression of other PDEs (PDE1A or 4B) were not associated with changes in IP receptor function. Manipulating PDZ domain of IP receptor, which binds PDZK1, prevented this interaction and restored the function and expression of IP receptor. 16K restored the expression of the IP receptor and its agonist induced cAMP accumulation via a cAMP-PKA-dependent mechanism.

Conclusions Our data show 16K increases basal and selexipag-mediated cAMP accumulation, relaxation and inhibition of proliferation in hypoxic-PASMC. We uncovered a novel PDZ-mediated interaction of PDE1C with the IP receptor, such that increased PDE1C associated with PAH would limit agonist-induced cAMP accumulation and relaxation by enhancing IP degradation. Together these data provide further evidence that PDE1 selective inhibitors could represent a novel PAH treatment alone and importantly enhance the response to prostacyclin agonists.

Conflict of Interest None
Correction: **BS18 Profiling endothelial gene expression in coronary atherosclerotic plaques in a human-like D374Y-PCSK9 hyperlipidaemic porcine model**


This Abstract has been corrected since it was first published. Co-authors Charles A Mein, Eva Wozniak, Daniele Carassiti, Abdul S Mahomed, Rob Krams and Ranil de Silva were missing. Their names and affiliations have now been added.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. Heart 2021;107:e10. doi:10.1136/heartjnl-2021-BCS.216corr1